Using artificial intelligence tools in answering important clinical questions: The KEYNOTE-183 multiple myeloma experience

The phase III, randomized, active-controlled, multicenter, open-label KEYNOTE-183 study (NCT02576977) evaluating pomalidomide and low dose dexamethasone (standard-of-care [SOC]) with or without pembrolizumab in patients with refractory or relapsed and refractory multiple myeloma (rrMM) was placed on full clinical hold by the US FDA on July 03, 2017 due to an imbalance in the number of deaths between arms. Clinically-led subgroup analyses are typically used to shed light on clinical findings. However, this approach is not always successful.

Source: Contemporary Clinical Trials - October 18, 2020 Category: Radiology Authors: Jason J.Z. Liao, Mohammed Z.H. Farooqui, Patricia Marinello, Jonathan Hartzel, Keaven Anderson, Junshui Ma, Christine K. Gause Source Type: research